Log in to your Inderes Free account to see all free content on this page.

Cessatech

3 following

ShowingAll content types

Regulatory press release11/13/2024, 12:00 PM

Cessatech: Third Quarter Report Q3-2024

Regulatory press release10/16/2024, 8:00 AM

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202

Regulatory press release9/2/2024, 8:00 AM

Cessatech and Proveca partnership - Q&A

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release8/26/2024, 6:30 AM

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

Regulatory press release8/21/2024, 6:30 AM

Cessatech: Second Quarter Report Q2-2024

Regulatory press release8/12/2024, 9:50 AM

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the forthcoming US launch of its lead program CT001

Regulatory press release8/2/2024, 1:00 PM

Key Cessatech priorities for the rest of the year

Regulatory press release7/26/2024, 2:00 PM

Cessatech: Grant of incentive warrants to Employees, CEO and the Board of Directors

Regulatory press release7/5/2024, 12:36 PM

Cessatech announces changes to the Board of Directors

Regulatory press release7/5/2024, 12:31 PM

Cessatech: Minutes of the Extraordinary General Meeting - 5 July 2024

Regulatory press release6/28/2024, 10:10 AM

Cessatech presents new data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001

Regulatory press release6/20/2024, 2:00 PM

Cessatech: EXTRAORDINARY GENERAL MEETING

Regulatory press release6/3/2024, 11:00 AM

Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators.

Regulatory press release5/27/2024, 12:53 PM

Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001

Regulatory press release5/15/2024, 6:45 AM

Cessatech: First Quarter Report Q1-2024

Regulatory press release4/18/2024, 8:46 AM

Cessatech: A short business update

Regulatory press release3/27/2024, 10:00 AM

Minutes from the Annual General Meeting in Cessatech A/S

Regulatory press release3/11/2024, 4:00 PM

Cessatech: Annual General Meeting - 27 March 2024

Regulatory press release2/29/2024, 8:00 AM

Cessatech A/S publishes Annual Report for the fiscal year 2023

Regulatory press release1/30/2024, 7:30 AM

Cessatech: CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.